TOFA Weight Loss Drug: The Fat-Burning Breakthrough That Might Finally Spare Your Muscle

There’s a new name floating around in weight-loss research circles, and it’s not another injectable with a catchy brand name. It’s TOFA — short for 5-tetradecyloxy-2-furoic acid, which is a mouthful, sure, but the science behind it might matter more than the syllables suggest. Early findings on the TOFA weight loss drug are pointing toward something Ozempic and its cousins have struggled with for years: losing fat without dragging muscle down with it.

What Exactly Is the TOFA Weight Loss Drug?

TOFA isn’t actually new. It was first made back in the 1970s and has floated around research labs for decades. What’s new is how a team at UC Berkeley just used it. Published in Science Advances on August 21, the study found that TOFA works completely differently than GLP-1 drugs like Ozempic, Wegovy, and Zepbound.

Here’s the distinction that matters: most weight-loss medications work by making you eat less. TOFA doesn’t touch appetite at all. Instead, it ramps up how much energy your body burns — in obese mice, researchers saw energy expenditure jump by as much as 18%, and the mice weren’t moving around more or running warmer to explain it. Something at the cellular level was just burning through more fuel.

Why Muscle Loss Has Become Ozempic’s Biggest Problem

To understand why people are paying attention to the TOFA weight loss drug, you have to understand what’s been bugging doctors about GLP-1 medications. These drugs are genuinely effective — nobody’s arguing that. But because they work by cutting how much you eat, your body often burns through muscle along with fat. Some research has put lean-mass losses at around 20% for people on these medications, which isn’t a minor side effect. Losing muscle affects strength, slows metabolism further, and can leave people more frail over time, especially as they get older.

That’s the gap TOFA seems to be filling. In the Berkeley trials, mice lost weight almost entirely from fat stores. Their muscle mass barely budged.

How TOFA Actually Works Inside the Body

The mechanism is a little more layered than “burn more calories.” TOFA blocks enzymes responsible for producing lipids like cholesterol and triglycerides, while simultaneously switching on genetic pathways tied to fat-burning and energy production. Berkeley professor Anders Näär, who led the research, explained the logic behind targeting this side of the equation rather than appetite. As he put it, weight comes down to two levers — eating less, or burning more — and since GLP-1 drugs already cover the first one, his team decided to go after the second.

Beyond the fat loss itself, mice on TOFA showed better blood sugar control, improved insulin sensitivity, lower triglycerides, and even signs of improvement in fatty liver disease. That’s a fairly wide net of benefits for one compound.

Could It Team Up With Ozempic and Wegovy?

This might be the most interesting part. Researchers didn’t just test TOFA on its own — they combined it with semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (found in Mounjaro and Zepbound). The mice on the combo treatments lost more weight and saw bigger improvements in blood sugar, insulin, and triglycerides than mice on either treatment alone.

That’s leading researchers to frame TOFA less as a replacement for existing drugs and more as a partner to them — something that could be layered on top of GLP-1 treatment rather than swapping it out entirely.

The Big Catch: This Is Still Just Mice

Before anyone gets ahead of themselves, it’s worth being blunt about where things actually stand. Every result connected to the TOFA weight loss drug so far comes from animal studies. Nobody has tested this in humans yet, and researchers have openly said its safety and effectiveness in people remain completely unknown. Some older compounds in the same drug family have run into issues with raised triglyceride levels, which is something the Berkeley team will need to rule out as they move forward.

The people behind the research aren’t sitting still, though. They’ve launched a company called ReRx Therapeutics to push the compound toward eventual use in patients, with dose-ranging safety studies already underway in animals ahead of any human trials.

What Comes Next

It’s early — genuinely early, not just the usual scientific caution talk. But the appeal of the TOFA weight loss drug is easy to understand: a treatment that targets fat directly while leaving muscle alone would solve one of the most talked-about downsides of the current generation of weight-loss medications. For the full breakdown of the science, UC Berkeley’s official research summary and the peer-reviewed study in Science Advances are worth a look if you want the details straight from the source.

For now, nobody should be trying to get their hands on TOFA outside of a lab. It’s not approved, it’s not tested in people, and researchers have specifically flagged concerns about anyone attempting to self-experiment with it. What’s exciting is the direction — not something you can act on yet.